A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Diabetic Kidney Disease, sponsored by Bayer. Completed at 975 sites in 48 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.
Among the 10 studies testing finerenone in Diabetic Nephropathies, this one has the largest enrollment, is one of 2 that started in 2015, is one of 3 in phase 3, and was the 3rd registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:
Huijie Zhang · Sites in China
Ages 18–70
Washington D.C. Veterans Affairs Medical Center · Sites in United States
Ages 20–90
Chittagong Medical College · Sites in Bangladesh
Ages 18+
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Ages 18+
College of Physicians and Surgeons Pakistan
Ages 18+
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7,352 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 108 across the 10 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 8 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
2 of the studies testing finerenone in Diabetic Nephropathies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07598864Phase 3Chittagong Medical College"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes" | 2027-05-01 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing finerenone in Diabetic Nephropathies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Finerenone tablet
Drug: Finerenone (BAY94-8862)
Matching placebo
Drug: Placebo
10 mg or 20 mg Finerenone tablet to be given orally, once daily.
Matching placebo to be taken orally, once daily.
The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result.
Time frame: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.
Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result.
Time frame: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
All-cause Hospitalization
Number of participants with first occurrence of a hospitalization event were reported as descriptive result.
Time frame: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months
All-cause Mortality
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
Time frame: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months
Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.
Time frame: From baseline up until Month 4
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death
Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result.
Time frame: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months
Study was conducted at multiple centers in 48 countries/regions between 17-Sep-2015 (first participant first visit) and 02-Feb-2021 (last participant last visit).
| Milestone | Finerenone | Placebo |
|---|---|---|
| Started | 3723 | 3714 |
| Treated | 3683 | 3658 |
| Included in fas | 3686 | 3666 |
| Completed | 3681 | 3653 |
| Not completed | 42 | 61 |
| Withdrew: Withdrawal by subject | 1 | 7 |
| Withdrew: Lost to follow-up | 4 | 6 |
| Withdrew: Gcp violations | 37 | 48 |
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result.
| Participants | Finerenone | Placebo |
|---|---|---|
| The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure. | 458 | 519 |
Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result.
| Participants | Finerenone | Placebo |
|---|---|---|
| The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death. | 350 | 395 |
Number of participants with first occurrence of a hospitalization event were reported as descriptive result.
| Participants | Finerenone | Placebo |
|---|---|---|
| All-cause Hospitalization | 1573 | 1605 |
Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.
| Participants | Finerenone | Placebo |
|---|---|---|
| All-cause Mortality | 333 | 370 |
First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.
| Ratio | Finerenone | Placebo |
|---|---|---|
| Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4 | 0.624 (0.606 to 0.642) | 0.922 (0.896 to 0.949) |
Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result.
| Participants | Finerenone | Placebo |
|---|---|---|
| The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death | 108 | 139 |
Collected over After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 36 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Finerenone | 339/3,686 (9.2%) | 1,158/3,683 (31.4%) | 1,797/3,683 (48.8%) |
| Placebo | 383/3,666 (10.4%) | 1,215/3,658 (33.2%) | 1,717/3,658 (46.9%) |
| Event | Finerenone | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 73/3683 | 113/3658 |
| Acute kidney injuryRenal and urinary disorders | 38/3683 | 46/3658 |
| CellulitisInfections and infestations | 40/3683 | 28/3658 |
| Urinary tract infectionInfections and infestations | 28/3683 | 39/3658 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 33/3683 | 25/3658 |
| HypoglycaemiaMetabolism and nutrition disorders | 17/3683 | 28/3658 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 27/3683 | 17/3658 |
| Diabetic nephropathyRenal and urinary disorders | 10/3683 | 26/3658 |
| Diabetes mellitusMetabolism and nutrition disorders | 20/3683 | 25/3658 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/3683 | 24/3658 |
| Event | Finerenone | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 318/3683 | 327/3658 |
| HyperkalaemiaMetabolism and nutrition disorders | 322/3683 | 159/3658 |
| HypertensionVascular disorders | 199/3683 | 296/3658 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 296/3683 | 260/3658 |
| Oedema peripheralGeneral disorders | 197/3683 | 278/3658 |
| Back painMusculoskeletal and connective tissue disorders | 260/3683 | 252/3658 |
| Urinary tract infectionInfections and infestations | 246/3683 | 220/3658 |
| DiarrhoeaGastrointestinal disorders | 235/3683 | 220/3658 |
| Upper respiratory tract infectionInfections and infestations | 225/3683 | 203/3658 |
| AnaemiaBlood and lymphatic system disorders | 210/3683 | 199/3658 |
Full analysis set (FAS): the FAS comprised all randomized participants (except those with critical GCP violations).
| Age, Continuous(Years) | Finerenone | Placebo | Total |
|---|---|---|---|
| Mean | 64.13 ± 9.67 | 64.13 ± 10.00 | 64.13 ± 9.83 |
| Sex: Female, Male(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| Female | 1158 | 1089 | 2247 |
| Male | 2528 | 2577 | 5105 |
| Ethnicity (NIH/OMB)(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 618 | 603 | 1221 |
| Not Hispanic or Latino | 3058 | 3057 | 6115 |
| Unknown or Not Reported | 10 | 6 | 16 |
| Race (NIH/OMB)(Participants) | Finerenone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 73 | 70 | 143 |
| Asian | 715 | 739 | 1454 |
| Native Hawaiian or Other Pacific Islander | 17 | 14 | 31 |
| Black or African American | 113 | 145 | 258 |
| White | 2672 | 2605 | 5277 |
| More than one race | 87 | 86 | 173 |
| Unknown or Not Reported | 9 | 7 | 16 |
| Urinary albumin-to-creatinine ratio (UACR)(milligram/gram (mg/g)) | Finerenone | Placebo | Total |
|---|---|---|---|
| Median | 302.36 (105.47 to 749.05) | 315.06 (111.24 to 731.01) | 308.18 (108.09 to 739.86) |
| Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2) | Finerenone | Placebo | Total |
|---|---|---|---|
| Mean | 67.62 ± 21.65 | 67.99 ± 21.74 | 67.80 ± 21.69 |
Showing the first 100 of 975 sites across 48 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, time point and process of data access. As such, Bayer commits to sharing upon request from qualified researcher's patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Sep 2015 to primary completion in Feb 2021, 64 months.
Results were first posted in Apr 2022, 1 year 2 months after primary completion.
Of 16 phase 3 interventional studies under Diabetic Nephropathies, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's 64 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone